NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis $1.16 -0.16 (-11.74%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$1.20 +0.03 (+3.00%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Century Therapeutics Stock (NASDAQ:IPSC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Century Therapeutics alerts:Sign Up Key Stats Today's Range$1.16▼$1.3250-Day Range$1.17▼$2.0052-Week Range$0.46▼$3.04Volume916,109 shsAverage Volume877,880 shsMarket Capitalization$211.56 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingHold Company Overview Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence. Founded in 2018 and based in Philadelphia, Pennsylvania, Century Therapeutics is a research- and development-stage company. Its work is focused on developing candidates for clinical testing; it does not have marketed therapies.AI Generated. May Contain Errors. Read More Century Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreIPSC MarketRank™: 1.565593196705 of 5 starsCentury Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 683rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCentury Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCentury Therapeutics has a consensus price target of $4.75, representing about 307.7% upside from its current price of $1.17.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Century Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Century Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.12% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 30.96, which indicates bearish sentiment.Change versus previous monthShort interest in Century Therapeutics has recently increased by 9.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.45 News SentimentCentury Therapeutics has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Century Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,213.00 in company stock.Percentage Held by Insiders2.40% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Century Therapeutics' insider trading history. Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPSC Stock News HeadlinesHC Wainwright Has Negative Estimate for IPSC FY2027 EarningsNovember 19 at 2:13 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Waters (WAT) and Century Therapeutics (IPSC)November 15, 2026 | theglobeandmail.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 21 at 1:00 AM | Paradigm Press (Ad)Century Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMCentury Therapeutics Q3 2026: Cash Runway, Narrowing Losses, and a Diabetes IND on DeckNovember 12, 2026 | 247wallst.comCentury Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesNovember 12, 2026 | globenewswire.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Stock Rated "Hold" by Wall Street BrokeragesNovember 12, 2026 | americanbankingnews.comCentury Therapeutics (IPSC) Expected to Release Quarterly Earnings on ThursdayNovember 11, 2026 | americanbankingnews.comSee More Headlines IPSC Stock Analysis - Frequently Asked Questions How have IPSC shares performed this year? Century Therapeutics' stock was trading at $0.9948 on January 1st, 2026. Since then, IPSC stock has increased by 17.1% and is now trading at $1.1650. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $200 million in an initial public offering on Thursday, June 17th 2021. The company issued 10,550,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Top institutional shareholders of Century Therapeutics include State Street Corp (1.39%), Goldman Sachs Group Inc. (0.25%) and American Century Companies Inc. (0.13%). Insiders that own company stock include Brent Pfeiffenberger, Chad Cowan, Gregory Russotti, Douglas Carr and Adrienne Farid. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Century Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include Werewolf Therapeutics (HOWL), Nkarta (NKTX), Rani Therapeutics (RANI), Tenaya Therapeutics (TNYA), Verizon Communications (VZ), Janux Therapeutics (JANX) and C4 Therapeutics (CCCC). Company Calendar Last Earnings11/12/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IPSC's financial health is in the Yellow zone, according to TradeSmith. IPSC has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IPSC CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees78Year Founded2018Price Target and Rating Average Price Target for Century Therapeutics$4.75 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+307.7%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-45.64% Return on Assets-35.94% Debt Debt-to-Equity RatioN/A Current Ratio8.74 Quick Ratio8.74 Sales & Book Value Annual Sales$109.16 million Price / Sales1.94 Cash Flow$0.01 per share Price / Cash Flow123.31 Book Value$1.16 per share Price / Book1.00Miscellaneous Outstanding Shares181,600,000Free Float177,239,000Market Cap$211.56 million OptionableOptionable Beta1.78 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:IPSC) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredI tested Elon's new tech myself and brought a camera crewElon Musk's new technology is already in 229 locations across 27 states plus D.C. In 2016, Forbes called testi...Brownstone Research | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.